Gene signatures in gastric cancer

Although the incidence and mortality of Gastric Cancer (GC) have fallen over the past 70 years, GC continues to be the second leading cause of cancer death and the fourth most common malignant neoplasia across the world. GC still represents a major clinical challenge because it has a poor prognosis and limited treatment options due to its relative resistance to radiotherapy and chemotherapy. At present, tumour stage provides the major prognostic variables used in clinical management of GC patients. However, GC with similar morphology may display different biological aggressiveness, prognosis and response to therapy.